Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
– Cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments –– Landmark research project is 100x larger than existing efforts –– Data will be generated from thousands of patients across multiple cancers.
– Cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments –
–. | June 1, 2023
Cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments Landmark research project